Intratumoral administration of CD1c (BDCA-1)+ and CD141 (BDCA-3)+ myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory advanced melanoma patients: a phase I clinical trial
出版年份 2022 全文链接
标题
Intratumoral administration of CD1c (BDCA-1)+ and CD141 (BDCA-3)+ myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory advanced melanoma patients: a phase I clinical trial
作者
关键词
-
出版物
Journal for ImmunoTherapy of Cancer
Volume 10, Issue 9, Pages e005141
出版商
BMJ
发表日期
2022-09-17
DOI
10.1136/jitc-2022-005141
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Unraveling the Effects of a Talimogene Laherparepvec (T-VEC)-Induced Tumor Oncolysate on Myeloid Dendritic Cells
- (2021) Jens Tijtgat et al. Frontiers in Immunology
- Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4+ T Cell Immunity
- (2019) Mikhail Binnewies et al. CELL
- Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma
- (2019) Praveen K. Bommareddy et al. OncoImmunology
- The clinical application of cancer immunotherapy based on naturally circulating dendritic cells
- (2019) Kalijn F. Bol et al. Journal for ImmunoTherapy of Cancer
- Talimogene laherparepvec monotherapy, an elegant alternative to systemic immunotherapy for the treatment of early metastatic melanoma
- (2019) V. Franke BRITISH JOURNAL OF DERMATOLOGY
- Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
- (2019) Caroline Robert et al. LANCET ONCOLOGY
- Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
- (2019) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2019) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort
- (2019) Diane Damotte et al. Journal of Translational Medicine
- Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer
- (2019) Harm Westdorp et al. Journal for ImmunoTherapy of Cancer
- NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control
- (2018) Jan P. Böttcher et al. CELL
- A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments
- (2018) Kevin C. Barry et al. NATURE MEDICINE
- Successful treatment with intralesional talimogene laherparepvec in two patients with immune checkpoint inhibitors refractory advanced melanoma
- (2018) Teofila Seremet et al. MELANOMA RESEARCH
- Opposing roles of eosinophils in cancer
- (2018) Sonja C. S. Simon et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12
- (2018) Christopher S. Garris et al. IMMUNITY
- Eosinophilic count as a biomarker for prognosis of melanoma patients and its importance in the response to immunotherapy
- (2017) Alvaro Moreira et al. Immunotherapy
- Elements of cancer immunity and the cancer–immune set point
- (2017) Daniel S. Chen et al. NATURE
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2017) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors
- (2017) Alexandra-Chloé Villani et al. SCIENCE
- Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial
- (2016) Robert H. I. Andtbacka et al. ANNALS OF SURGICAL ONCOLOGY
- Critical Role for CD103 + /CD141 + Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma
- (2016) Edward W. Roberts et al. CANCER CELL
- Expansion and Activation of CD103 + Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition
- (2016) Hélène Salmon et al. IMMUNITY
- Density of immunogenic antigens does not explain the presence or absence of the T-cell–inflamed tumor microenvironment in melanoma
- (2016) Stefani Spranger et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The tumour microenvironment harbours ontogenically distinct dendritic cell populations with opposing effects on tumour immunity
- (2016) Damya Laoui et al. Nature Communications
- Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade
- (2016) P.-L. Chen et al. Cancer Discovery
- Human CD1c+ DCs are critical cellular mediators of immune responses induced by immunogenic cell death
- (2016) Stefania Di Blasio et al. OncoImmunology
- Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy
- (2016) Hasan Rehman et al. Journal for ImmunoTherapy of Cancer
- Protamine-stabilized RNA as an ex vivo stimulant of primary human dendritic cell subsets
- (2015) Annette E. Sköld et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells
- (2015) G. Schreibelt et al. CLINICAL CANCER RESEARCH
- Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
- (2015) Robert H.I. Andtbacka et al. JOURNAL OF CLINICAL ONCOLOGY
- Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
- (2015) Stefani Spranger et al. NATURE
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- A new paradigm for tumor immune escape: β-catenin-driven immune exclusion
- (2015) Stefani Spranger et al. Journal for ImmunoTherapy of Cancer
- Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell Immunity
- (2014) Miranda L. Broz et al. CANCER CELL
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Human CD1c+ dendritic cells secrete high levels of IL-12 and potently prime cytotoxic T-cell responses
- (2013) G. Nizzoli et al. BLOOD
- Natural Human Plasmacytoid Dendritic Cells Induce Antigen-Specific T-Cell Responses in Melanoma Patients
- (2013) J. Tel et al. CANCER RESEARCH
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- Dendritic Cells: Master Regulators of the Immune Response
- (2013) I. Mellman Cancer Immunology Research
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started